Swiss National Bank Buys 65,800 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Swiss National Bank grew its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 23.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 347,800 shares of the company's stock after acquiring an additional 65,800 shares during the period. Swiss National Bank owned about 0.16% of Hims & Hers Health worth $8,410,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Crewe Advisors LLC purchased a new stake in Hims & Hers Health during the 4th quarter worth $28,000. Raleigh Capital Management Inc. grew its position in shares of Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 1,100 shares in the last quarter. Smartleaf Asset Management LLC increased its position in shares of Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after purchasing an additional 1,413 shares during the last quarter. US Bancorp DE raised its stake in Hims & Hers Health by 346.7% during the fourth quarter. US Bancorp DE now owns 1,943 shares of the company's stock valued at $47,000 after buying an additional 1,508 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Hims & Hers Health during the 4th quarter valued at approximately $48,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Stock Performance

HIMS traded down $0.60 during trading on Tuesday, reaching $36.81. The company had a trading volume of 7,106,533 shares, compared to its average volume of 13,881,126. The firm's 50-day simple moving average is $39.44 and its 200 day simple moving average is $29.05. The company has a market cap of $8.18 billion, a price-to-earnings ratio of 83.72 and a beta of 1.37. Hims & Hers Health, Inc. has a 12-month low of $11.20 and a 12-month high of $72.98.

Remove Ads

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Activity

In other news, CEO Andrew Dudum sold 128,127 shares of the company's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $33.98, for a total value of $4,353,755.46. Following the transaction, the chief executive officer now owns 173,655 shares in the company, valued at $5,900,796.90. This represents a 42.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Soleil Boughton sold 268,932 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the sale, the insider now owns 169,803 shares of the company's stock, valued at approximately $4,712,033.25. This represents a 61.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 998,244 shares of company stock worth $35,662,485 over the last quarter. Corporate insiders own 17.71% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently commented on HIMS shares. Truist Financial upped their price target on shares of Hims & Hers Health from $24.00 to $39.00 and gave the stock a "hold" rating in a research report on Wednesday, February 26th. Morgan Stanley lowered shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and raised their price target for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. BTIG Research initiated coverage on Hims & Hers Health in a report on Tuesday, January 7th. They set a "buy" rating and a $35.00 price target on the stock. Bank of America increased their price target on Hims & Hers Health from $21.00 to $22.00 and gave the stock an "underperform" rating in a research note on Tuesday, March 18th. Finally, Needham & Company LLC raised their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a research note on Tuesday, February 25th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, Hims & Hers Health has a consensus rating of "Hold" and a consensus target price of $37.31.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.